{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:12:39Z","timestamp":1788502359634,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Interleukin-17A (IL-17A) inhibitors are effective therapies for psoriasis (PsO) and psoriatic arthritis (PsA), yet they may induce or exacerbate inflammatory bowel disease (IBD). Vunakizumab is a novel humanized anti-IL-17A monoclonal antibody approved in China in 2024; post-marketing real-world data on its gastrointestinal safety profile remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a 54-year-old male PsA patient who developed acute severe ulcerative colitis (UC) approximately one week after the third injection of vunakizumab, representing the first reported case of vunakizumab-associated IBD in the literature. The patient exhibited marked hepatic enzyme elevation (alanine aminotransferase [ALT] 213 U\/L, aspartate aminotransferase [AST] 189 U\/L), representing one of the most significant liver injuries reported in this context. The Naranjo Adverse Drug Reaction Probability Scale score was 7 (\u201cprobable\u201d). Vunakizumab was immediately discontinued; intravenous methylprednisolone 60 mg\/day was administered to induce remission. Following acute-phase control, the patient was switched to guselkumab (an anti-IL-23p19 monoclonal antibody) for maintenance therapy, achieving dual remission of intestinal and articular manifestations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Vunakizumab can induce severe UC. As a newly approved IL-17A inhibitor in China, early post-marketing safety surveillance should remain vigilant for IBD risk. The underlying mechanism may involve disruption of the intestinal epithelial barrier and compensatory upregulation of IL-23 following IL-17A blockade. The early treatment period (within the first 3 months) represents a high-risk window. Upon diagnosis, immediate drug withdrawal, corticosteroid-induced remission, and prioritized conversion to an IL-23 inhibitor (such as guselkumab) may be considered as a potential option to achieve dual control of intestinal, skin, and joint disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1904435","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:29:39Z","timestamp":1788499779000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Vunakizumab-induced severe ulcerative colitis during treatment of psoriatic arthritis: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Yanan","family":"Cui","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Shengli Oilfield Central Hospital","place":["Dongying, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Shengli Oilfield Central Hospital","place":["Dongying, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shengli Oilfield Central Hospital","place":["Dongying, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15397","article-title":"Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents","volume":"50","author":"Yamada","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0233781","DOI":"10.1371\/journal.pone.0233781","article-title":"Risk for development of inflammatory bowel disease under inhibition of interleukin 17: a systematic review and meta-analysis","volume":"15","author":"Burisch","year":"2020","journal-title":"PLoS One"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1594998","article-title":"Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"500475","DOI":"10.2147\/BTT.S500475","article-title":"Vunakizumab for IL-17A-mediated diseases: a review in psoriasis and spondyloarthritis","volume":"20","author":"Yan","year":"2026","journal-title":"Biol Targets Ther."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2009.03240.x","article-title":"Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease","volume":"129","author":"Onishi","year":"2010","journal-title":"Immunology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.22551\/2022.37.0904.10227","article-title":"New onset severe ulcerative colitis following ixekizumab therapy","volume":"9","author":"Morosanu","year":"2022","journal-title":"Arch Clin Cases"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-01936-w","article-title":"Severe drug-associated colitis with Crohn's features in setting of ixekizumab therapy for chronic plaque psoriasis","volume":"21","author":"Mu","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.14309\/crj.2018.56","article-title":"Rapid onset of inflammatory bowel disease after receiving secukinumab infusion","volume":"5","author":"Wang","year":"2018","journal-title":"ACG Case Rep J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.17235\/reed.2019.5841\/2018","article-title":"The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?","volume":"111","author":"Rodr\u00edguez Moncada","year":"2019","journal-title":"Rev Esp Enferm Dig"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-025-02153-8","article-title":"IL-17A inhibitor-induced ulcerative colitis treated with an anti-IL-23 antibody","volume":"18","author":"Ishida","year":"2025","journal-title":"Clin J Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy063","article-title":"Emergence of inflammatory bowel disease during treatment with secukinumab","volume":"12","author":"Fobelo Lozano","year":"2018","journal-title":"J Crohns Colitis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12876-019-1067-0","article-title":"Crohn's-like disease in a patient exposed to anti-interleukin-17 blockade (ixekizumab) for the treatment of chronic plaque psoriasis: a case report","volume":"19","author":"Smith","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"9404505","DOI":"10.1155\/2020\/9404505","article-title":"Secukinumab-induced inflammatory bowel disease in a patient treated for chronic plaque psoriasis and psoriatic arthritis: a case report and review of the role of novel biologic agents targeting the p19 subunit of IL-23","volume":"2020","author":"Darch","year":"2020","journal-title":"Case Rep Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1769290","DOI":"10.1155\/2023\/1769290","article-title":"New-onset Crohn's disease following initiation of secukinumab: a case report and review of the role of IL-17 in the pathogenesis of Crohn's disease","volume":"2023","author":"Khouri","year":"2023","journal-title":"Case Rep Gastrointest Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-023-01893-9","article-title":"Colitis induced by IL-17A-inhibitors","volume":"17","author":"Gr\u00fcmme","year":"2023","journal-title":"Clin J Gastroenterol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.030124.ntt","article-title":"New-onset, treatment-resistant inflammatory bowel disease after administration of secukinumab for plaque psoriasis: a case report and review of the existing literature","volume":"35","author":"Krikelis","year":"2024","journal-title":"Mediterr J Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1159\/000547522","article-title":"Case report: secukinumab (interleukin-17 inhibitor) and ulcerative colitis flare-the double-edged sword","volume":"19","author":"Ongay","year":"2025","journal-title":"Case Rep Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.51821\/87.3.12874","article-title":"New onset inflammatory bowel disease after initiation of anti-IL-17A treatment: a case series","volume":"87","author":"Geldof","year":"2024","journal-title":"Acta Gastroenterol Belg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.70148","article-title":"Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection","volume":"16","author":"Tabbarah","year":"2024","journal-title":"Cureus"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1904435\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:29:40Z","timestamp":1788499780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1904435\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2026.1904435"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1904435","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1904435"}}